Roland E. Schmieder

TL;DR: The CAD-as mentioned in this paper registry as mentioned in this paper is a prospective observational multicenter national registry for chronic kidney disease (CKD) with ≥ 3,300 patients with angiographically documented coronary artery disease (coronary artery disease [CAD]; ≥50% stenosis in at least 1 coronary artery) being enrolled at 32 centers and assigned to 6 different groups according to their estimated glomerular filtration rate and proteinuria.

TL;DR: Hyper-responsiveness to angiotensin II is related to an increased left ventricular mass in hypertensive subjects independent of blood pressure, as well as the normotensive and hypertensive groups.

TL;DR: This observation point to a decrease of total sodium content in patients with type 2 diabetes known to be salt sensitive and prone to cardiovascular complications, that might be mitigated by SGLT-2 inhibition.

TL;DR: In line with other studies comprising CKD cohorts, patients’ morbidity and in-hospital mortality increased with the degree of renal impairment, and cardiologists’ drug prescription rates in CAD-REF were still lower especially in advanced CKD stages compared to cohorts treated by nephrologists.

TL;DR: Blood pressure reduction per se is not necessarily a marker of successful renal nerve ablation, and reduction in splanchnic autotransfusion following renal denervation has not been previously demonstrated and denotes attenuation of (renal) sympathetic efferent activity and could serve as a markers of procedural success.